Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NGSX CUSIP suspended. FINRA deleted symbol:
http://otce.finra.org/DLDeletions
NGSX is severely delinquent in filing their Financials and corporate filing obligations to the SEC. On Feb. 20, 2015 the SEC suspended 8 stocks from the Delinquent SEC Filers list, and it is likely that more delinquent Filers will be suspended.
Since Jan 1st, 2010 the SEC has suspended over 1290 stocks for Financials delinquencies. All of those Suspended stocks had their stock registrations revoked.
Shareholders should contact the company and pressure the Mgmt to file their delinquent Financials because ALL shareholders would be wiped out IF the SEC suspends the stock.
NGSX is on the list of delinquent filers:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110680509
NGSX 0.018 +Up 300% Alerted and is on our list!!
NGSX - Targets 0.009 / 0.012 / 0.02 / 0.03
* Our next Multi-BAGGER !!
http://stockcharts.com/h-sc/ui?s=NGSX&p=D&yr=0&mn=9&dy=0&id=p41018864076
http://stockcharts.com/h-sc/ui?s=NGSX&p=D&yr=0&mn=9&dy=25&id=p00611396735
http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=23986&srchyr=2013&SearchStr=ngsx
Sure hope that Santa Claus left a tube of Mayan-inspired red hot chili pepper juice salve/gel product in the Xmas stockings of all of the loyal NGSX "investors" who voted with their hard-earned bux for capsaisin development and getting RICH-Rich-rich on their gambling instincts.
How did that ever work out? Just another write-off for losers on their IRA Form 10140 Schedule D, perhaps....
Youse be advertising for a commercial venture, IMHO.
In the past, my contributions were real enough. Sort of the skeptic on this message board about commercializing ancient Mayan Indian folk medicine for scientific effect. Youse can look it up in a couple of years' posting on this message board.
Not good medicine; not good financing; not good management; not a good product line for investment. All IMHO.
Thanks for the personal attack. Glad you brought more useful information here, technical or humble opinion.
Looks more like SPAMMING than bringing fresh, useful information to stuck bagholders. All IMHO.
~ $NGSX ~ Daily Par Sar Buy Signal ~ Criteria alert triggered during a recent trading session!
$NGSX has just triggered the "Parabolic SAR Buy Signals" scan criteria at Stockcharts.com
~ http://tinyurl.com/SAR-BUY ~
For a more in Depth study and DD profile, similar to the one contained in this link: ~ http://tinyurl.com/DDexample ~
Click the following link and type ticker or brief message asking me about the DD: ~ http://tinyurl.com/GET-THE-DD ~
What does the scan "Parabolic SAR Buy Signals" mean? Below is an image example and study link.
~ http://stockcharts.com/school/doku.php?id=chart_school:technical_indicators:parabolic_sar ~
To find other similar posts of "NGSX" utilize the links that follow.
Search MACDgyver's "Parabolic SAR Buy Signals" posts: ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=ParSarBuyScan ~
Search MACDgyver's posts for symbol "NGSX": ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=NGSX ~
Search Ihub for "NGSX" posts: ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=NGSX ~
For more in depth training and information visit Chartschool on the Stockcharts page.
~ http://stockcharts.com/school/doku.php?id=chart_school ~
Also don't forget the Ihub Edu Channel.
~ http://investorshub.advfn.com/boards/education.aspx ~
c
Maybe the Arabs and Japs are starting to fold their tents and leave red hot chili pepper juice nostrums to the Mayans! All IMHO.
Not sure what's going on here
Crashed and burned, did it?
Old Mayan medicine men must not have been happy with commercialization of red hot pepper juice formula.
What's next to steal, atabrine? All IMHO.
not sure "The Asset Sales, together, constitute the sale of substantially all of the assets of the Company"
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
June 24, 2013 (June 18, 2013)
Date of Report (date of earliest event reported)
NEUROGESX, INC.
(Exact name of Registrant as specified in its charter)
Delaware 001-33438 94-3307935
(State or other jurisdiction of
incorporation or organization)
(Commission
File Number)
(I.R.S. Employer
Identification Number)
999 Baker Street, Suite 200, San Mateo, California 94404
(Address of principal executive offices)
(650) 358-3300
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 18, 2013, NeurogesX, Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”). The following is a brief description of each matter voted upon at the Special Meeting, as well as the number of votes cast for or against each matter and the number of abstentions and broker non-votes with respect to each matter.
1. The proposal to approve the sale of certain of the Company’s assets to Acorda Therapeutics, Inc. (“Acorda”) pursuant to the Asset Purchase Agreement, dated as of April 15, 2013, by and among the Company and Acorda (such sale is referred to as the “Acorda Sale”), and the sale of certain other assets in which Healthcare Royalty Partners L.P. (“HC Royalty”) has a security interest securing the Company’s obligations under the Financing Agreement, dated as of April 29, 2010 (as amended), between HC Royalty and the Company, by HC Royalty, as the secured party, in a Uniform Commercial Code Article 9 process prior to the closing of the Acorda Sale (together with the Acorda Sale, referred to as the “Asset Sales”) was approved by the Company’s stockholders. The Asset Sales, together, constitute the sale of substantially all of the assets of the Company. The votes on this matter were as follows:
Votes for
Against
Withheld
Broker non-vote
19,100,913
1,082,614 34,816 223,005
2. The proposal to approve one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the first proposal was approved by the Company’s stockholders. The votes on this matter were as follows:
Votes for
Against
Withheld
Broker non-vote
19,326,108
1,055,321 59,919 0
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NEUROGESX, INC.
By:
/s/ Stephen F. Ghiglieri
Stephen F. Ghiglieri
Executive Vice President, Chief
Operating Officer
and Chief Financial Officer
Date: June 24, 2013
3
No, not all assets, certain assets
yep thanks, all assets will be sold.
Thanks.....definitely positive news.
It's really don't matter what stockholders think or votes, the outcome remain the same.
In this case they put a stick on shareholders ask jmho:))
do u think stockholders will approve something bad? i don't think so:
"Prior to the special meeting of NeurogesX stockholders to approve the transactions under the APA, pursuant to an
Acknowledgement of Default and Release Agreement, NeurogesX will acknowledge that there exists events of default under
the FA, whereupon HC Royalty is expected to conduct a sale of the Astellas Territory Assets under Article 9 of the Uniform"
did u read this?
NGSXE .015$ 33M OS 10M FLOAT NOBRAINER,FDA PLAYER, ONGOGOING PH3 PLUS FDA APPROVED DRUGS,SOLD TO ACORDA BUT MAY BE ENTITLED TO BIG ROYALTIES IF APPROVAL COMES IN NEXT YEARS,MARKET CAP 400K $ WAS MULTI DOLLAR PLAYER,AT 0.05 MARKET CAP COULD BE LESS THAN 2MLN$ FOR A MULTI MILLION $ DRUG AND ROYALTIES,NO BANKRUPTCY HERE, REGULATORY NEWS MAY COME AT ANY MOMENT
alert NGSXE PPS MAY STABILIZE AROUND .05 OR 1.6MLN$ MC, ACORDA THERAPEUTICS WILL RELEASE KEY DATA AND REGULATORY DECISIONS IN NEXT WEEKS/MONTHS/YEARS,EVERY PH3 ADVANCEMENT WILL PUSH PPS IMHO,ONE OF THE BIGGEST MARKET MISS, TILL .05 VERY LOW RESISTANCE
See.....Looks like they stole the assets...er sold
Nothing left shareholders holding the bag here eom
It's really don't matter for NGX-1998 Phase 3 development. They going to sell all the asset and shares holders getting nothing eom
On watch as well eom
news can hit anytime: http://www.neurogesx.com/img/pipelinemay172012.gif
It means non-bulletin board
NGSXE: Failure To Comply With NASD 6530: Added to NBB (NGSX)
http://www.otcbb.com/asp/dailylist_detail.asp?d=05/20/2013&mkt_ctg=OTCBB
3 Research Reports on may 2013,something is brewing http://finance.yahoo.com/q/rr?s=NGSXE+Research+Reports
Phase 2 clinical trial in PHN patients,and the Company believes that NGX-1998 is ready to enter Phase 3 development.
33M OS 10M FLOAT,52 wk.range:.01-.41,470k cap as of May 15, 2013
FDA PLAYER NGSXE .015 WILL BE 0.50 WHEN/IF DRUG APPROVED:
knulp
Thursday, May 16, 2013 11:01:37 AM
Re: ash111 post# 3009360
Post # of 3009457
FDA PLAYER NGSXE .015 WILL BE 0.50 WHEN/IF DRUG APPROVED,REMEMBER DRUG WAS ALREADY APPROVED,PH3 FOR FURTHER INDICATION LED BY ACORDA, IN CASE OF APPROVAL A LOT OF MONEY TO NGSXE AND COMMONS, COMPANY ISN'T IN BANKRUPTCY BUT SOLD MOST OF ITS ASSETS TO ACORDA FOR MONEY,POTENTIAL ROYALTIES, BATGAIN ATHESE PPS IMO
NGSXE .015$ 33M OS 10M FLOAT NOBRAINER,FDA PLAYER, ONGOGOING PH3 PLUS FDA APPROVED DRUGS,SOLD TO ACORDA BUT MAY BE ENTITLED TO BIG ROYALTIES IF APPROVAL COMES IN NEXT YEARS,MARKET CAP 400K $ WAS MULTI DOLLAR PLAYER,AT 0.05 MARKET CAP COULD BE LESS THAN 2MLN$ FOR A MULTI MILLION $ DRUG AND ROYALTIES,NO BANKRUPTCY HERE, REGULATORY NEWS MAY COME AT ANY MOMENT
alert NGSXE PPS MAY STABILIZE AROUND .05 OR 1.6MLN$ MC, ACORDA THERAPEUTICS WILL RELEASE KEY DATA AND REGULATORY DECISIONS IN NEXT WEEKS/MONTHS/YEARS,EVERY PH3 ADVANCEMENT WILL PUSH PPS IMHO,ONE OF THE BIGGEST MARKET MISS, TILL .05 VERY LOW RESISTANCE
Was that starter a "hunch" buy or do youse have a hobby of catching falling sharp objects?
Before youse threw your money on the blanket, did youse do ANY deep due diligence on this slippery slider?
Buying into a stock that has drawn the dreaded "E" suffix takes guts, but often leaves spilled blood on the blankie. All IMHO.
Grabbed a starter here.
Starting to look interesting....watching closely
Choppy trading yesterday for Not Good SeX Ever.
Sub-penny stock next week?
Don't ride the roller-coaster unless you are prepared to vomit! All IMHO.
Could be more than that! Did youse not catch that the symbol now is NGSXE (Not Good SeX Ever!)
"Late" filing may have turned into "UNABLE to file."
Their last 8k filing was reading like a prelude to closing the door, the party is over.
When a stock symbol attracts the "E" suffix, it ain't simply a matter of filing late. All IMHO.
Followers
|
21
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
554
|
Created
|
05/09/07
|
Type
|
Free
|
Moderators |
http://www.neurogesx.com/
http://finance.yahoo.com/q/h?s=NGSX
http://www.insidercow.com/history/company.jsp?company=ngsx&B1=Search!
NeurogesX, Inc., a biopharmaceutical company, engages in the development and commercialization of novel pain management therapies. It primarily focuses on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP), and painful diabetic neuropathy (PDN). The company�s lead product candidate NGX-4010 is a synthetic capsaicin-based topical patch to manage pain associated with peripheral neuropathic pain conditions, has completed two pivotal Phase 3 clinical trials in PHN and HIV-DSP. It is also developing NGX-1998, a non-patch liquid formulation of synthetic capsaicin, and an opioid analgesic for use in managing pain associated with other chronic pain conditions, such as cancer pain. The company was founded in 1998 as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in 2000. NeurogesX is headquartered in San Carlos, California.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |